 "Strides Shasun gets US regulator nod for Ibuprofen capsules")
The firm's wholly-owned subsidiary Strides Pharma Global has received nod for 200-mg Ibuprofen capsules from the US health regulator, Strides Shasun said. The nod comes after an approval cycle of almost six years.
The US over-the -counter market for the painkiller is $300 million, including a private label market of $60 million. The Bengaluru-based company looks garner at least 20 per cent of this private label market share. The product will be commercialised in fourth quarter of the current financial year and will be manufactured at the company's oral dosage unit in Bengaluru.
The company has 74 cumulative abbreviated new drug application filings with USFDA of which 45 have been approved and 29 are pending approval.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app